— Know what they know.
Not Investment Advice
Also trades as: 0JBU.L (LSE) · $vol 0M

NTLA NASDAQ

Intellia Therapeutics, Inc.
1W: +3.7% 1M: +7.5% 3M: +13.7% YTD: +33.3% 1Y: -52.0% 3Y: -53.9% 5Y: -90.7%
$12.28
+1.02 (+9.06%)
After Hours: $12.16 (-0.12, -0.98%)
Weekly Expected Move ±8.1%
$9 $10 $11 $12 $13
NASDAQ · Healthcare · Biotechnology · Tech Score Neutral · Power 46 · $1.7B mcap · 134M float · 3.32% daily turnover · Short 43% of daily vol
Credit Risk of going bust: higher than 68% of companies Debt: 4.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.10 (down 99.2%), Intellia Therapeutics, Inc. would be worth roughly what it owes.
Total debt $73.4M against a stock market value of $1.58B.
Distance to default 3.59 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $36.7M (short-term plus half of long-term), stock volatility 96.2%; Altman Z'' -4.42. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$842M -29.3% ▼
5Y CAGR: +4.5%
Total Liabilities
$171M -46.5% ▼
5Y CAGR: +2.7%
Shareholders Equity
$671M -23.0% ▼
5Y CAGR: +5.0%
Cash & Investments
$450M -25.2% ▼
5Y CAGR: -5.5%
Total Debt
$93M -55.6% ▼
5Y CAGR: +18.9%
Net Debt
-$62M -395.7% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$123M$524M$227M$189M$155M
Short-Term Investments$625M$669M$685M$412M$294M
Cash & ST Investments$749M$1.2B$912M$602M$450M
Net Receivables$2M$4M$36M$9M$9M
Inventory$0$0$0$0$0
Other Current Assets$0$20M$50M$30M$68M
Total Current Assets$769M$1.2B$998M$640M$528M
Property, Plant & Equip.$100M$161M$148M$247M$124M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$425M$142M$155M$44M$36M
Other Non-Current Assets$0$0$0$260M$155M
Total Non-Current Assets$525M$303M$303M$551M$314M
Total Assets$1.3B$1.5B$1.3B$1.2B$842M
— Liabilities —
Accounts Payable$10M$5M$7M$15M$20M
Short-Term Debt$0$0$0$0$26M
Deferred Revenue$64M$44M$22M$21M$7M
Other Current Liabilities$20M$22M$7M$55M$50M
Total Current Liabilities$126M$127M$115M$111M$104M
Long-Term Debt$0$0$0$0$67M
Other Non-Current Liab.$0$24M$39M$0$0
Total Non-Current Liabilities$128M$158M$136M$208M$67M
Total Liabilities$254M$285M$251M$319M$171M
— Equity —
Common Stock$7K$9K$9K$10K$12K
Retained Earnings-$703M-$1.2B-$1.7B-$2.2B-$2.6B
Accumulated OCI-$3M-$7M-$2M$605K$1M
Total Stockholders Equity$1.0B$1.2B$1.1B$872M$671M
Total Liabilities & Equity$1.3B$1.5B$1.3B$1.2B$842M
— Key Metrics —
Total Debt$74M$131M$115M$210M$93M
Net Debt-$49M-$393M-$111M$21M-$62M
Total Investments$1.1B$811M$840M$457M$330M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms